ROS1-Positive Lung Non-Small Cell Carcinoma

ROS1-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 0
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: —
Top sponsor: —
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06797362	Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors	available	—	—	Nuvalent Inc.INDUSTRY	10	Aug 25, 2026	clinicaltrials
NCT06841874	Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC(Tale EAP)	no longer available	—	—	Nuvation Bio Inc.INDUSTRY	0	Dec 24, 2025